c-kit inhibitor masitinib induces reactive oxygen species-dependent apoptosis in c-kit-negative HepG2 cells.


Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
15 Sep 2022
Historique:
received: 27 04 2022
revised: 17 07 2022
accepted: 01 08 2022
pubmed: 9 8 2022
medline: 8 9 2022
entrez: 8 8 2022
Statut: ppublish

Résumé

Tumor-specific growth signal inhibition is a major anticancer strategy. Receptor tyrosine kinases (RTKs) are the most upstream receptors for growth signaling in cancer. Therefore, inhibition of RTKs has been proposed as an efficient therapeutic target. Masitinib, a c-kit inhibitor of the c-kit RTK, was developed to treat mastocytoma in dogs. In humans, however, the antitumor efficacy of masitinib was found to be attenuated against tumor cells with mutations of the c-kit gene. Here, we report that masitinib induced cell death via the intrinsic apoptotic pathway in HepG2, a c-kit-negative hepatocellular carcinoma cell line. In masitinib-treated HepG2 cells, increases in intracellular reactive oxygen species levels, loss of mitochondrial membrane potential, and cleavage of caspase-9 were observed, activating the intrinsic apoptotic pathway. Moreover, the cytotoxicity of masitinib to HepG2 cells was suppressed by treatment with the antioxidant N-acetyl-

Identifiants

pubmed: 35940239
pii: S0014-2999(22)00444-7
doi: 10.1016/j.ejphar.2022.175183
pii:
doi:

Substances chimiques

Benzamides 0
Piperidines 0
Pyridines 0
Reactive Oxygen Species 0
Thiazoles 0
KIT protein, human EC 2.7.10.1
Proto-Oncogene Proteins c-kit EC 2.7.10.1
JNK Mitogen-Activated Protein Kinases EC 2.7.11.24
masitinib M59NC4E26P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

175183

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Yuta Semba (Y)

Division of Life Science and Engineering, College of Science and Engineering, Tokyo Denki University, Hatoyama, Hiki-gun, Saitama, Japan.

Shintaro Yamamoto (S)

Division of Life Science and Engineering, College of Science and Engineering, Tokyo Denki University, Hatoyama, Hiki-gun, Saitama, Japan.

Shunsuke Takahashi (S)

Division of Life Science and Engineering, College of Science and Engineering, Tokyo Denki University, Hatoyama, Hiki-gun, Saitama, Japan.

Takahisa Shinomiya (T)

Division of Life Science and Engineering, College of Science and Engineering, Tokyo Denki University, Hatoyama, Hiki-gun, Saitama, Japan.

Yukitoshi Nagahara (Y)

Division of Life Science and Engineering, College of Science and Engineering, Tokyo Denki University, Hatoyama, Hiki-gun, Saitama, Japan. Electronic address: yuki@mail.dendai.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH